Extract
A recent editorial in the European Respiratory Journal highlighted the strategic importance of the Clinical Research Collaborations (CRCs) launched in 2013 by the European Respiratory Society (ERS) [1]. These have the aim of 1) promoting the exchange of research ideas among clinicians and affiliated scientists in Europe and/or globally; 2) building an infrastructure for prospective clinical research; 3) securing additional funding through national and European Union funding streams; and 4) facilitating the planning, implementation, evaluation and publication of clinical and translational studies at pan-European level and beyond. So far, there are currently 17 ongoing CRCs that cover eight major respiratory disease domains (airway diseases, interstitial lung diseases, pulmonary vascular diseases, sleep and breathing disorders, respiratory critical care, paediatric respiratory diseases, respiratory infections and thoracic oncology), all of them linked to one or more ERS assemblies [2–12].
Abstract
The ERS launches a new Clinical Research Collaboration (CADSET) to study the determinants and implications of different lung function trajectories through life http://ow.ly/nf4E30nGsJG
Acknowledgements
We are grateful for the support from the ERS office in Lausanne, Switzerland, in logistics and organisation of CADSET.
Footnotes
Current members of the CADSET Clinical Research Collaboration are as follows. Co-chairs and WG5 co-leaders: Alvar Agusti and Jadwiga A. Wedzicha. WG1 co-leaders: Gavin Donaldson, Rosa Faner and Robab Breyer-Kohansal. WG2 co-leaders: Anke H. Maitland-van der Zee and Erik Melén. WG3 co-leaders: James P. Allinson, Lowie E.G.W. Vanfleteren and Jørgen Vestbo. WG4 co-leaders: Ian M. Adcock, Lies Lahousse and Maarten van den Berge. Additional CADSET members: Peter Alter, Ferran Barbe, Christopher E. Brightling, Marie-Kathrin Breyer, Otto C. Burghuber, Maribel Casas, Kian Fan Chung, Borja G. Cosío, Fatima Crispi, Jordi de Batlle, Jean-William Fitting, Judith Garcia, Jenny Hallberg, Sylvia Hartl, Deborah Jarvis, Alexander Mathioudakis, Laurent Nicod, Alberto Papi, Andrew Ritchie, Torben Sigsgaard, Peter J. Sterk, Anders Ullman, Kilian Vellvé, Claus Vogelmeier, Asa M. Wheelock, Craig E. Wheelock and Antonio Spanevello.
Conflict of interest: A. Agusti reports personal fees from AstraZeneca, Chiesi and Nuvaira, and grants and personal fees from Menarini and GSK, outside the submitted work.
Conflict of interest: R. Faner reports support from GSK for an advisory board, and grants from GSK and Menarini, outside the submitted work.
Conflict of interest: G. Donaldson has nothing to disclose.
Conflict of interest: E. Heuvelin reports multi-sponsored study fees from Chiesi, Sanofi, Grifols, Novartis, Insmed, Zambon, TEVA, GlaxoSmithKline and CSL Behring, outside the submitted work. E. Heuvelin is an employee of the European Respiratory Society.
Conflict of interest: R. Breyer-Kohansal reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and Chiesi, personal fees from Novartis, and grants from GlaxoSmithKline, Menarini and Pfizer, during the conduct of the study.
Conflict of interest: E. Melén has nothing to disclose.
Conflict of interest: A.H. Maitland-van der Zee reports research grants from Boehringer Ingelheim, GSK and Novartis, and she participated in an advisory board from AstraZeneca, outside the submitted work.
Conflict of interest: J. Vestbo reports personal fees for consultancy for COPD Phase 2 and 3 programme and payment for lectures including service in speaker bureaux, from GlaxoSmithKline, Chiesi Pharmaceuticals, Boehringer Ingelheim, Novartis and AstraZeneca, and an unconditional grant for biomarker research at Manchester University Hospital NHS Foundation Trust from Boehringer Ingelheim, outside the submitted work.
Conflict of interest: J.P. Allinson has nothing to disclose.
Conflict of interest: L.E.G.W. Vanfleteren reports grants and personal fees from AstraZeneca, personal fees from Pulmonx, Novartis, GSK and Menarini, grants from Fisher & Paykel, and personal fees and non-financial support from Chiesi, outside the submitted work.
Conflict of interest: M. van den Berge has nothing to disclose.
Conflict of interest: I.M. Adcock has nothing to disclose.
Conflict of interest: L. Lahousse reports grants from AstraZeneca and Chiesi (both awards), and expert consultation for Boehringer Ingelheim GmbH and Novartis, outside the submitted work.
Conflict of interest: G. Brusselle reports personal fees for advisory boards and lecture fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva, and personal fees for advisory boards from Sanofi, outside the submitted work.
Conflict of interest: J.A. Wedzicha reports research grants to her institution from GSK and Johnson & Johnson, research grants for early COPD cohorts from GSK, AstraZeneca, Boehringer Ingelheim, Novartis and Chiesi, and meeting expenses from Novartis, Boehringer Ingelheim, AstraZeneca and GSK, outside the submitted work.
Support statement: Funding was received from the European Respiratory Society.
- Received January 30, 2019.
- Accepted February 3, 2019.
- Copyright ©ERS 2019